TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05751629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib was administered.
Study: NCT02533869

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Description: Low-dose computed tomography for suspected acute uncomplicated appendicitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
Study: NCT02459704

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semilunar coronally positioned flap
Description: Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
Study: NCT03205371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
Study: NCT02459704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap
Description: Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (Emdogain)
Description: Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
Study: NCT01712100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avapro
Study: NCT04426643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study: NCT00959543

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI and clinical investigation

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI and clinical investigation
Study: NCT02252432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: A single dose of IV methadone (0.2 mg/kg) preinduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: A single dose of IV methadone (0.2 mg/kg) preinduction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + methadone
Description: Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + methadone
Description: Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
Study: NCT01468298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isostretching
Description: All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global Posture Reeducation
Description: All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
Study: NCT02339922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05264480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone augmentation with minimally invasive corticotomy (piezotomy)
Description: Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone augmentation without corticotomy
Description: Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated.
Study: NCT05535049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.
Study: NCT01115257

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vitrectomy
Description: The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: panretinalphotocoagulation
Description: Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
Study: NCT03484598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
Study: NCT02059967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo IGART
Study: NCT00481156

Intervention type: OTHER
Group type: OTHER
Intervention: Retest in Health Controls
Description: Pre/Post test performance and neuroimaging only
Study: NCT01766778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAF237 (vildagliptin)
Description: Vildagliptin 50mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAF237 (vildagliptin)
Description: Vildagliptin 50mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum tolerance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin maximum tolerance dose
Study: NCT04665076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto CAR-T
Description: Biological: Auto CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide,Fludarabine
Description: Drug: Cyclophosphamide,Fludarabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis
Study: NCT02701478

Intervention type: DRUG
Group type: OTHER
Intervention: N2O exposure
Description: The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
Study: NCT03487796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MySTYLE
Description: Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
Study: NCT02678910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian Cryopreservation
Description: The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
Study: NCT04253561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally once a day, beginning on Cycle 1, Day 1 through Day 21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 420 mg every 3 weeks
Study: NCT03522922

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaroller
Description: The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaroller
Description: The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin C
Description: The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Vitamin C
Description: The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
Study: NCT04531033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus MPH734
Description: After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus MPH734
Description: After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo made to match dietary supplement being tested.
Study: NCT04871217

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-RGD PET-imaging
Description: Patients will undergo cardiac 68Ga-NODAGA-RGD PET in order to detect myocardial αVβ3 integrin expression 3-14 days after an acute myocardial infarction or within 4 weeks before and 2 weeks after re-opening of chronic coronary occlusion. Echocardiography of cardiac function will be performed at the time of PET imaging and repeated 6 months later.
Study: NCT01995617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline, 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline, 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline, 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Low Dose
Description: The GEN-004 Low Dose contains 10µg of each of the three antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Low Dose + Adjuvant
Description: The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Mid Dose
Description: The GEN-004 Mid Dose contains 30µg of each of the three antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 Mid Dose + Adjuvant
Description: The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 High Dose
Description: The GEN-004 High Dose contains 100µg of each of the three antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-004 High Dose + Adjuvant
Description: The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
Study: NCT02776007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libre Flash CGMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Measurement Blood Glucose
Description: Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
Study: NCT02059967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02803554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Blood plasma from donors aged 25 years or younger
Study: NCT00986076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin 40 mg / 500 ml in Balanced Salt Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution
Description: Intraocular infusion of Balanced Salt solution
Study: NCT03612661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
Study: NCT03970239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)
Description: Imaging of the serotoninergic system with Positron Emission Tomography using \[11 Carbon\]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile (\[11C\]-DASB) and \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of \[11C\]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of \[18F\]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
Description: Imaging of the serotoninergic system with Positron Emission Tomography using \[18 Fluorine\]-altanserin (\[18F\]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of \[18F\]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
Study: NCT02510144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prep Chlorhexidine
Description: 3 day preoperative skin prep prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Prep Benzoyl Peroxide
Description: 3 day preoperative skin prep prior to surgery
Study: NCT02124265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeraLyte 90
Description: 1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used.
Study: NCT00490282

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT Treatment Over 6-7 Weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: ART Treatment Over 6-7 Weeks
Study: NCT06065566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention.